Bing

SEARCH HISTORY

AEterna Zentaris (NASDAQ:AEZS)‘s stock had its “buy” rating reissued by equities research analysts at Maxim Group in a research note issued to investors on Thursday, Market Beat reports. AEZS has been the subject of a number of other recent …
Ticker Report · 16 hours ago
Aeterna Zentaris Inc. (AEZS - Snapshot Report) announced that it has completed patient enrolment (n=500) in the open-label, randomized-controlled phase III ZoptEC (Zoptarelin Doxorubicin in Endometrial Cancer) study on its oncology candidate zoptarelin ...
ZACKS · 1 day ago
Endometrial Cancer
Aeterna Zentaris Inc. AEZS announced that it has completed patient enrolment ... Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report
Yahoo Finance · 1 day ago
More from Bing News
Maxim Group reaffirmed their buy rating on shares of AEterna Zentaris (NASDAQ:AEZS) in a report released on Wednesday. Maxim Group currently has a $2.00 price objective on the biopharmaceutical company’s stock. AEterna Zentaris (NASDAQ …
sleekmoney.com · 6/19/2015
you might come away with the mistaken notion that these two companies are comparable except in stock price, which is just not true. Company Ticker Chief Scientist Journal 1st authorships Top Journals AEterna Zentaris AEZS Richard Sachse 3 Oncogene ...
Seeking Alpha · 6/30/2015
Chief Scientific Officers
AEterna Zentaris (NASDAQ:AEZS)‘s stock had its “buy” rating restated by Maxim Group in a research note issued on Wednesday. They currently have a $2.00 target price on the biopharmaceutical company’s stock. AEterna Zentaris (NASDAQ:AEZS ...
Mideast Times · 6/18/2015
Aeterna Zentaris Inc. ( AEZS) was a big mover last session ... This continues the recent uptrend for the company as the stock is now up 17.65% since Mar, 10, 2015. None of the estimates for this biotechnology stock were revised over the past 30 days.
NASDAQ · 3/23/2015
AEterna Zentaris (NASDAQ:AEZS)‘s stock had its “strong-buy” rating restated by Zacks in a research report issued to clients and investors on Thursday. They currently have a $0.75 price objective on the stock. Zacks‘s price objective indicates a ...
wkrb13.com · 4/30/2015
Frontline Ltd. (FRO)’S monthly performance stands at 20.590% with an analyst rating of 3.2 (Click To Expand Current Stock Data:) Aeterna Zentaris Inc. (AEZS) of the Healthcare sector is down -2.57% so far today trading at $0.28 at a volume of 757168 …
wallstreetscope.com · 6/12/2015
To see the stock peel back from that resistance a second time and then blast past it on the third effort speaks volumes about how persistent the bulls are at this point. To fully appreciate just how big of a paradigm shift AEZS has just logged, however ...
Smallcap Network · ByJames E. Brumley · 8/28/2014